스피라프릴염산염

개요Spirapril hydrochloride is a new ACE inhibitor introduced in Finland for the treatment of hypertension. Spirapril is orally active and rapidly absorbed and converted to the active diacid spiraprilat which produces a reduction in blood pressure similar to that seen with enalapril and captopril. Spirapril has been reported to be well tolerated and exhibits an apparently lower incidence of cough compared with other ACE inhibitors. The elimination of spirapril occurs via both renal and hepatic routes so that no dosage adjustment is required for patients with renal impairment. In patients with severe congestive heart failure, spirapril has demonstrated beneficial hemodynamic effects with a duration of action >24 hours.